Clinical Study 2
Corroborating Clinical Confirmation:
Patients with Joint Discomfort
This second randomized, double-blind, placebo-controlled study explored how a 250mg dose of TamaFlex affected subjects with induced joint discomfort. Sixty (60) subjects (male and female 40-70 years old) were chosen and randomized for the baseline visit and three follow-up visits on days 5, 28, and 56, where the WOMAC self-assessment test was used as the primary efficacy measure.
Findings from Clinical Study 2
Results found that, by day 5, the TamaFlex group started showing:
Improvement in comfort
Improvement in walking distance covered
Improvement in stiffness
Improvement in stair climbing time
Improvement in physical activity
Improvement in knee flexion scores
Of note with this study is that objective BioMarkers were tested and reviewed. Researchers also found significant reductions in TNF-α, hsCRP, and IL-6 levels in TamaFlex subjects, indicating the support of healthy inflammation systemically and specifically of the knee . TamaFlex also significantly reduced Matrix metalloproteinase-3 (MMP-3) activity, the compound that is involved with the breakdown of connective tissue. No serious adverse events were observed.
More TamaFlex Clinical Studies
Clinical Study 1
A 90-Day Study with Healthy Participants
Clinical Study 3
Confirms 5-day Joint Health Benefits: Patients With Mild Discomfort